2021-12-03 Meeting notes

Date

03 Dec 2021

Attendees

Committee Member	Present	Absent
Kuffel, Gina (NIH/NCI) [C]
Pihl, Todd (NIH/NCI) [C]
Unknown User (leblancak)
Otridge, John (NIH/NCI) [C]
Kim, Erika (NIH/NCI) [E]
Sommers, Connie (NIH/NCI) [E]
Debbie Knapp
Toby Hecht
Anju Singh
Unknown User (parchmentr)

Goals

Discuss updates to ICDC and define emerging strategies and priorities

Box Folder

https://nih.box.com/s/5wmrgl85z6fxpo3ldhanxzmmqq3ekfy7

Relevant Links for Today's Meeting

Outstanding Action Items

Kuffel, Gina (NIH/NCI) [C] Add Gardner et. al paper to candidate publication list: https://www.nature.com/articles/s42003-019-0487-2

Discussion items

Item	Who	Talking Points
Steering Committee Meeting Updates	Unknown User (parchmentr)
ICDC Next Phase	Unknown User (hechtt)	Next steps for soliciting a small group of comparative oncology researchers who are ICDC users Recruitment at the next PRECINCT SC meeting (Dec. 10th)
DGAB Updates	Kuffel, Gina (NIH/NCI) [C]	Updates to existing studies GLIOMA01- 77 case-level vcf and 77 tbi files added (80.2 MB) New studies released MGT01- Molecular Homology and Differences Between Spontaneous Canine Mammary Cancer and Human Breast Cancer (68 files, 289.3 GB) C0TC022- A Contemporaneous Controlled Study of the Standard of Care in Dogs with Appendicular Osteosarcoma (2 files, 0.08 MB) Communications with authors of first candidate publication test case from Candidate Publication List Data Submission Request was completed on their behalf Email was sent by Warren Kibbe on behalf of DGAB Folder containing all submission artifacts for this test case can be found here Data ingestion PanCancer study to begin soon Folder containing all submission artifacts for this study can be found here Data Transfer Agreement is in final stages of legal approval Folder containing any artifacts related to the DTA can be found here
Data Use Guidelines	Kuffel, Gina (NIH/NCI) [C]	Sent to Jason Cristofaro for review Questions remain around the commercial use of the data Link to draft document can be found here
User Research for ICDC by the Office of Communications and Public Liaison (OCPL)	Kuffel, Gina (NIH/NCI) [C]	In kick-off and planning phase Finalizing user interview dates: The UX company is targeting January or early February Google Analytics reports have been shared with the UX contractor for their discovery period Recruitment is critical- these will be folks targeted for user interviews DGAB members PRECINCT members Pharmacodynamics group Other groups, channels, or individuals?
ICDC Site Updates	Kuffel, Gina (NIH/NCI) [C]	Production release targeted for Dec. 15th New slide deck available (if we want to spend the time talking about features)

Minutes (Not Verbatim)

Previous Meeting Minutes (Not Verbatim)

DK- Data may be coming into ICDC from the Promislow and Rod Page from Colorado State.

TH- In the Aging study are they looking at specific breeds?

DK- Several represented. Working heavily with the Broad and data made available there. The cancer data may be available to be deposited into ICDC.

EK- One of the reasons we pushed for user research on canine is we have a lot of flexibility to make improvements. It will be interesting to do this at this stage and then possibly again in the future. Please send relevant questions for the study if they exist.

RP- We may need NCI to take a look that the MTA once it is drafted. Claudia Hayward has been working with this on us.

TH- I can make arrangements for that.

RP- Not an acquisition, just a reimbursement.

TH- NCI should at least take a look and give their approval. Regarding tech transfer, will commercial companies use this data? Is there an issue with a commercial company using ICDC data to make a product?

EK- Data use guidelines are coming soon.

TH- Keep these policies consistent with other data commons.

TH- Need to start seriously thinking about the next Task Order. We need a small group to brainstorm and present to the Executive Committee and then the Steering Committee. Not sure if Debbie can be involved because she is external. I propose myself, Connie, Erika, and Ralph. I'm not getting any feedback from anyone about what they think we should be doing.

CS- Maybe include Elaine, to include a non-cancer perspective.

TH- Let's plan for mid-November. Can we talk more with John Otridge and determine his role. What about Anju? I will reach out to Anju.

TH- All authors working with canines will now know if they have additional data.

AL- We have many folks in the SC that may have pipelines that exist, others may be willing to share their pipelines.

CS- I have a grantee that we should talk with about sharing pipelen

AL- Not many people understand molecular implications of canine lymphoma, little cross-validation of IHc. Not fair to say they don't match, the right set of tools is needed. 30% of case load is Lymphoma. Such a diverse disease.

Content

Space Tools